Skip Navigation
Search Menu
 

Departments

Daniel Goldstein

Class Notes

News and notes from and about our graduates.

Circling the Dome

A new center for Zika treatment, celebrating a Lasker, high-intensity treatment for high-use patients, defending against cyberattacks and more.

sweating illustration

Medical Rounds

A laser focus for epilepsy, sweating it out, sickle cell and opioids, looking to the biofilm in colon cancer, and more.

Hopkins Reader

Randall Packard tells where efforts to improve global health have fallen short. Plus: Essays on the history of the Children’s Medical and Surgical Center (in a nod to the Lane), and what to do when antidepressants fail.

Forum

illustration

Post-Op

The scientific community is getting serious about fixing the replication problem in research.

letter illustration

Letters

This issue’s letter from the editor and reader responses.

Second Opinion

Keeping kids healthy involves giving the HPV vaccine. So what’s stopping us?

In Focus

Hopkins employees in rainbos scrubs at Baltimore Pride

Showing Pride

More than 300 people from Johns Hopkins marched in the annual Baltimore Pride Parade in July, a celebration of the LGBTQ community. Led by a “scrubs rainbow” and accompanied by a Lifeline ambulance and a Blue Jay shuttle, the Johns Hopkins crowd’s enthusiasm earned it the Best Walking Group award in the parade.

In 2017, The Johns Hopkins Hospital will join a growing number of leading academic medical centers in offering gender-affirming therapies for transgender patients, including sex reassignment surgery and hormonal treatment, as part of a range of support options available.

Watch a video featuring Johns Hopkins participants in the Pride Parade.

Horizons

Zika Infected Organoid

Zeroing in on Zika

Two classes of compounds already in the pharmaceutical arsenal may work against mosquito-borne Zika virus infections, says a research team, including Johns Hopkins researchers, which screened 6,000 existing compounds currently in late-stage clinical trials or already approved for human use for other conditions.

The screening process identified several compounds, reported in Nature Medicine in August, that showed the ability to hinder or halt the progress of the Zika virus in lab-grown human neural cells.

“It takes years, if not decades, to develop a new drug,” says Hongjun Song, director of the stem cell biology program at Johns Hopkins. “In this sort of global health emergency, we don’t have that kind of time.”

Next up: studies of the drugs in animals to see if they can combat Zika in vivo.

Save the Date!

Make a Gift

chalkboard drawing of gift and heart rate

You can choose to support a specific cause at Johns Hopkins about which you are passionate, or you can make a contribution that will support our priorities in research, patient care and medical education.

Learn More